These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3804907)

  • 41. Cefotetan pharmacokinetics in volunteers with various degrees of renal function.
    Smith BR; LeFrock JL; Thyrum PT; Doret BA; Yeh C; Onesti G; Schwartz A; Zimmerman JJ
    Antimicrob Agents Chemother; 1986 May; 29(5):887-93. PubMed ID: 3460524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacokinetics of temocillin in patients with normal and impaired renal function.
    Boelaert J; Daneels R; Schurgers M; Lambert AM; Van Landuyt HW; Mellows G; Wolf J; Swaisland AJ
    J Antimicrob Chemother; 1983 Apr; 11(4):349-56. PubMed ID: 6853404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.
    Lunell E; Borgå O; Larsson R
    Eur J Clin Pharmacol; 1984; 26(1):87-93. PubMed ID: 6714295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function.
    Pearson JG; Antal EJ; Raehl CL; Gorsch HK; Craig WA; Albert KS; Welling PG
    Clin Pharmacol Ther; 1986 Mar; 39(3):318-24. PubMed ID: 3081293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure.
    Houghton GW; Dennis MJ; Gabriel R
    Br J Clin Pharmacol; 1985 Feb; 19(2):203-9. PubMed ID: 3986078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function.
    Lanao JM; Domínguez-Gil A; Tabernero JM; De Castro S
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):171-5. PubMed ID: 447438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-dose pharmacokinetics of cefpirome in patients with renal impairment.
    Lameire N; Malerczyk V; Drees B; Lehr K; Rosenkranz B
    Clin Pharmacol Ther; 1992 Jul; 52(1):24-30. PubMed ID: 1623690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency].
    Kumon H; Mizuno A; Nasu Y; Tsugawa M; Kishi M; Ohmori H
    Jpn J Antibiot; 1989 Jan; 42(1):200-7. PubMed ID: 2709618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic studies in volunteers with renal impairment.
    Keller F; Czock D
    Int J Clin Pharmacol Ther; 1998 Nov; 36(11):594-8. PubMed ID: 9849749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.
    Mihindu JC; Scheld WM; Bolton ND; Spyker DA; Swabb EA; Bolton WK
    Antimicrob Agents Chemother; 1983 Aug; 24(2):252-61. PubMed ID: 6685452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration.
    Lanao JM; Dominguez-Gil A; Tabernero JM; Molina HD
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):271-5. PubMed ID: 7107075
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency.
    Kampf D; Schurig R; Korsukewitz I; Brückner O
    Antimicrob Agents Chemother; 1981 Dec; 20(6):741-6. PubMed ID: 7325641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationships between renal function and disposition of oral ciprofloxacin.
    Forrest A; Weir M; Plaisance KI; Drusano GL; Leslie J; Standiford HC
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1537-40. PubMed ID: 3190182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics in the elderly. Studies on ciprofloxacin.
    Lebel M; Bergeron MG
    Am J Med; 1987 Apr; 82(4A):108-14. PubMed ID: 3555025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.
    Pendyala L; Madajewicz S; Creaven PJ
    Cancer Res; 1985 Nov; 45(11 Pt 2):5936-8. PubMed ID: 4053065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of ceftezole in patients with normal and impaired renal function.
    Ohkawa M; Kuroda K
    Chemotherapy; 1980; 26(4):242-7. PubMed ID: 7389424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.